Back to news

Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

ACCESSWIRE•19/11/2026•09:00 ET
0

Key Highlights

  • ➤Lexaria completed final dosing on schedule in five-week GLP-1-H26-7 human study
  • ➤Study compares two oral DHT-semaglutide compositions against Novo’s commercially available Wegovy tablets
  • ➤Laboratory analyses, quality control and data review now precede any study-result disclosure
  • ➤Study tests DHT-semaglutide tablet and capsule formulations with SNAC over multiple weeks

KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® ("Novo") commercially available Wegovy® tablets, over a 5-week duration (the "Study").

Final visits were completed this week by all Study participants within all Study arms. With dosing complete and final blood samples taken, the Study work will now shift to laboratory sample analyses, quality control and review of all data, and then reporting.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in